Published On: July 31st, 2018Categories: CAR T-Cell, Newsletters, Search and Analytics

In this issue, we have covered a couple of hot topics that are currently trending in the biotech and cloud-tech industries. We have talked about the FDA’s approval of tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.), a CD19-directed genetically modified autologous T-cell immunotherapy, to include treatment of patients with relapsed or refractory large B-cell lymphoma. Tisagenlecleucel is the only CAR T-cell therapy to receive FDA approval for two distinct indications. The report includes a chart of major commercial players in the CAR T-cell space and a Year-on-Year trend on the number of patents and patent applications from 2012 to 2018.

We have also discussed Microsoft’s Azure Internet of Things (IoT) Edge and its key features. A quick look at the patent filings claiming Edge or Fog computing revealed Intel has the most number of filings in this space. Read more on this report.

Have any content requests?

You can let us know at [email protected]

Get the latest IP data, insights and inspiration directly delivered to your inbox

Categories